A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders
Identifieur interne : 005132 ( Main/Merge ); précédent : 005131; suivant : 005133A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders
Auteurs : Steven J. Frucht [États-Unis] ; Yvette Bordelon [États-Unis] ; William H. Houghton [États-Unis] ; Dayton Reardan [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-10.
English descriptors
- KwdEn :
- Adjuvants, Anesthesia (adverse effects), Adjuvants, Anesthesia (therapeutic use), Adult, Aged, Central Nervous System Depressants (adverse effects), Central Nervous System Depressants (therapeutic use), Drug Administration Schedule, Drug Therapy, Combination, Dystonia (diagnosis), Dystonia (drug therapy), Essential Tremor (diagnosis), Essential Tremor (drug therapy), Ethanol (adverse effects), Ethanol (therapeutic use), Female, Humans, Male, Myoclonus (diagnosis), Myoclonus (drug therapy), Pilot Projects, Severity of Illness Index, Sodium Oxybate (adverse effects), Sodium Oxybate (therapeutic use), Treatment Outcome, Xyrem, ethanol, myoclonus, sodium oxybate, tremor, γ‐hydroxybutyric acid.
- MESH :
- chemical , adverse effects : Adjuvants, Anesthesia, Central Nervous System Depressants, Ethanol, Sodium Oxybate.
- chemical , therapeutic use : Adjuvants, Anesthesia, Central Nervous System Depressants, Ethanol, Sodium Oxybate.
- diagnosis : Dystonia, Essential Tremor, Myoclonus.
- drug therapy : Dystonia, Essential Tremor, Myoclonus.
- Adult, Aged, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Pilot Projects, Severity of Illness Index, Treatment Outcome.
Abstract
Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol‐responsive movement disorders in an open‐label, dose‐titration, add‐on, 8‐week trial. All five patients (one with severe alcohol‐responsive posthypoxic myoclonus, two with ϵ‐sarcoglycan–linked myoclonus–dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose‐dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20605
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001F70
- to stream Istex, to step Curation: 001F70
- to stream Istex, to step Checkpoint: 002455
- to stream PubMed, to step Corpus: 003016
- to stream PubMed, to step Curation: 003016
- to stream PubMed, to step Checkpoint: 003257
- to stream Ncbi, to step Merge: 001296
- to stream Ncbi, to step Curation: 001296
- to stream Ncbi, to step Checkpoint: 001296
Links to Exploration step
ISTEX:13DB9E68088F40250D33A2690DEBC082CC1E3214Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name></author><author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:13DB9E68088F40250D33A2690DEBC082CC1E3214</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20605</idno><idno type="url">https://api.istex.fr/document/13DB9E68088F40250D33A2690DEBC082CC1E3214/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001F70</idno><idno type="wicri:Area/Istex/Curation">001F70</idno><idno type="wicri:Area/Istex/Checkpoint">002455</idno><idno type="wicri:doubleKey">0885-3185:2005:Frucht S:a:pilot:tolerability</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15986420</idno><idno type="wicri:Area/PubMed/Corpus">003016</idno><idno type="wicri:Area/PubMed/Curation">003016</idno><idno type="wicri:Area/PubMed/Checkpoint">003257</idno><idno type="wicri:Area/Ncbi/Merge">001296</idno><idno type="wicri:Area/Ncbi/Curation">001296</idno><idno type="wicri:Area/Ncbi/Checkpoint">001296</idno><idno type="wicri:doubleKey">0885-3185:2005:Frucht S:a:pilot:tolerability</idno><idno type="wicri:Area/Main/Merge">005132</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University Medical Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University Medical Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Orphan Medical, Inc., Minnetonka, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Orphan Medical, Inc., Minnetonka, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-10">2005-10</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1330">1330</biblScope><biblScope unit="page" to="1337">1337</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">13DB9E68088F40250D33A2690DEBC082CC1E3214</idno><idno type="DOI">10.1002/mds.20605</idno><idno type="ArticleID">MDS20605</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Anesthesia (adverse effects)</term><term>Adjuvants, Anesthesia (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Central Nervous System Depressants (adverse effects)</term><term>Central Nervous System Depressants (therapeutic use)</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Dystonia (diagnosis)</term><term>Dystonia (drug therapy)</term><term>Essential Tremor (diagnosis)</term><term>Essential Tremor (drug therapy)</term><term>Ethanol (adverse effects)</term><term>Ethanol (therapeutic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Myoclonus (diagnosis)</term><term>Myoclonus (drug therapy)</term><term>Pilot Projects</term><term>Severity of Illness Index</term><term>Sodium Oxybate (adverse effects)</term><term>Sodium Oxybate (therapeutic use)</term><term>Treatment Outcome</term><term>Xyrem</term><term>ethanol</term><term>myoclonus</term><term>sodium oxybate</term><term>tremor</term><term>γ‐hydroxybutyric acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adjuvants, Anesthesia</term><term>Central Nervous System Depressants</term><term>Ethanol</term><term>Sodium Oxybate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Anesthesia</term><term>Central Nervous System Depressants</term><term>Ethanol</term><term>Sodium Oxybate</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dystonia</term><term>Essential Tremor</term><term>Myoclonus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term><term>Essential Tremor</term><term>Myoclonus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Pilot Projects</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol‐responsive movement disorders in an open‐label, dose‐titration, add‐on, 8‐week trial. All five patients (one with severe alcohol‐responsive posthypoxic myoclonus, two with ϵ‐sarcoglycan–linked myoclonus–dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose‐dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted. © 2005 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.20605"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name></author><author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:13DB9E68088F40250D33A2690DEBC082CC1E3214</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20605</idno><idno type="url">https://api.istex.fr/document/13DB9E68088F40250D33A2690DEBC082CC1E3214/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001F70</idno><idno type="wicri:Area/Istex/Curation">001F70</idno><idno type="wicri:Area/Istex/Checkpoint">002455</idno><idno type="wicri:doubleKey">0885-3185:2005:Frucht S:a:pilot:tolerability</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University Medical Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University Medical Center, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Orphan Medical, Inc., Minnetonka, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Orphan Medical, Inc., Minnetonka, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-10">2005-10</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1330">1330</biblScope><biblScope unit="page" to="1337">1337</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">13DB9E68088F40250D33A2690DEBC082CC1E3214</idno><idno type="DOI">10.1002/mds.20605</idno><idno type="ArticleID">MDS20605</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Xyrem</term><term>ethanol</term><term>myoclonus</term><term>sodium oxybate</term><term>tremor</term><term>γ‐hydroxybutyric acid</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol‐responsive movement disorders in an open‐label, dose‐titration, add‐on, 8‐week trial. All five patients (one with severe alcohol‐responsive posthypoxic myoclonus, two with ϵ‐sarcoglycan–linked myoclonus–dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose‐dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted. © 2005 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders.</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J" last="Frucht">Steven J. Frucht</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Columbia University Medical Center, New York, New York 10032, USA. sf216@columbia.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University Medical Center, New York, New York 10032</wicri:regionArea><wicri:noRegion>New York 10032</wicri:noRegion></affiliation></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H" last="Houghton">William H. Houghton</name></author><author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20605</idno><idno type="RBID">pubmed:15986420</idno><idno type="pmid">15986420</idno><idno type="wicri:Area/PubMed/Corpus">003016</idno><idno type="wicri:Area/PubMed/Curation">003016</idno><idno type="wicri:Area/PubMed/Checkpoint">003257</idno><idno type="wicri:Area/Ncbi/Merge">001296</idno><idno type="wicri:Area/Ncbi/Curation">001296</idno><idno type="wicri:Area/Ncbi/Checkpoint">001296</idno><idno type="wicri:doubleKey">0885-3185:2005:Frucht S:a:pilot:tolerability</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders.</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J" last="Frucht">Steven J. Frucht</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Columbia University Medical Center, New York, New York 10032, USA. sf216@columbia.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University Medical Center, New York, New York 10032</wicri:regionArea><wicri:noRegion>New York 10032</wicri:noRegion></affiliation></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H" last="Houghton">William H. Houghton</name></author><author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Anesthesia (adverse effects)</term><term>Adjuvants, Anesthesia (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Central Nervous System Depressants (adverse effects)</term><term>Central Nervous System Depressants (therapeutic use)</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Dystonia (diagnosis)</term><term>Dystonia (drug therapy)</term><term>Essential Tremor (diagnosis)</term><term>Essential Tremor (drug therapy)</term><term>Ethanol (adverse effects)</term><term>Ethanol (therapeutic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Myoclonus (diagnosis)</term><term>Myoclonus (drug therapy)</term><term>Pilot Projects</term><term>Severity of Illness Index</term><term>Sodium Oxybate (adverse effects)</term><term>Sodium Oxybate (therapeutic use)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adjuvants, Anesthesia</term><term>Central Nervous System Depressants</term><term>Ethanol</term><term>Sodium Oxybate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Anesthesia</term><term>Central Nervous System Depressants</term><term>Ethanol</term><term>Sodium Oxybate</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dystonia</term><term>Essential Tremor</term><term>Myoclonus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term><term>Essential Tremor</term><term>Myoclonus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Pilot Projects</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol-responsive movement disorders in an open-label, dose-titration, add-on, 8-week trial. All five patients (one with severe alcohol-responsive posthypoxic myoclonus, two with epsilon-sarcoglycan-linked myoclonus-dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose-dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005132 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005132 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:13DB9E68088F40250D33A2690DEBC082CC1E3214
|texte= A pilot tolerability and efficacy trial of sodium oxybate in ethanol‐responsive movement disorders
}}
| This area was generated with Dilib version V0.6.23. |  |